Viewing nowCombinationLovatitan Tablet 20/160 mg
Valsartan 160mg · Rosuvastatin Calcium Micronized 20.8mg
Tablet · Prescription medication · Combination
LG Chemical Co., Ltd.

MFDS item code 201309652 · Approved 2013.10.10 · Insurance code 668902660
Improvement of dyslipidemia; treatment of hypertension and heart failure; reduction of cardiovascular disease and mortality risk
This medication contains two active ingredients, valsartan and rosuvastatin, used for specific patients. Valsartan is mainly used for patients with essential hypertension and heart failure, and to reduce the risk of death after myocardial infarction. It is particularly effective for heart failure patients intolerant to ACE inhibitors. Rosuvastatin is used as an adjunct therapy for patients with hypercholesterolemia and dyslipidemia and helps with homozygous familial hypercholesterolemia. It is also used to reduce the risks of stroke, myocardial infarction, and revascularization due to cardiovascular diseases. This medication works synergistically to improve cardiovascular health through the management of blood pressure and blood lipids.
This medicine should be administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When coadministering a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed by dose increases over several weeks to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into account. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or greater. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: The daily dose of this medicine should preferably not exceed 80 mg in patients with mild or moderate hepatic impairment. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, treatment may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, particularly during the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. It is safer not to use this medication in women who are allergic to it, pregnant or possibly pregnant, or breastfeeding. Patients with severe liver or kidney dysfunction, muscle diseases, or a history of specific angioedema should not take this medication. Elderly patients or those with high potassium levels, or with impaired liver function should exercise extra caution while taking this medication, and liver function tests should be repeated as needed. This medication may cause muscle pain, muscle weakness, and rarely severe muscle damage (rhabdomyolysis); therefore, if any unusual muscle symptoms occur, it is important to inform healthcare professionals immediately. While taking this medication, liver function tests and muscle enzyme level tests may be required, and usage should be suspended if there are any abnormal signs. Drug interactions may occur when taken with other medications, so it is essential to inform the physician or pharmacist of any other medications being taken. This medication lowers blood pressure and may cause symptoms of hypotension (dizziness, fainting, etc.), so caution is advised while driving or operating machinery. There are no specific antidotes for overdose, so it is important to avoid exceeding the recommended dose, and to visit a healthcare facility immediately if unusual symptoms occur. It is advisable to avoid use in children and adolescents as the safety and efficacy of this medication have not been adequately established. This medication should be kept out of the reach of children and should not be transferred to another container.
Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial edema, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased blood levels of liver aminotransferases, increased blood creatine phosphokinase, increased blood potassium, increased gamma-glutamyl transferase, musculoskeletal rigidity, limb pain, sensory loss, anxiety, upper respiratory infection, pharyngitis, tonsillitis, spinal canal stenosis, aphasia, oral bleeding, vomiting, insulin-dependent diabetes mellitus, diabetes complications, leg fracture, spinal fracture, fracture, skin mass, second-degree atrioventricular block, vestibular neuritis, retinal detachment, unspecified skin tumor-like condition, herpes zoster, intervertebral disc herniation, hemoptysis, sputum disease, bronchitis, sensory disturbance, hoarseness, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, elevated blood pressure, exacerbation of hypertension, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, unspecified dermatitis, localized skin reaction, palpitations, exacerbation of angina, auditory disturbance, overactive bladder, increased serum creatinine, benign prostatic hyperplasia, laceration, headache, dizziness, constipation, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, myasthenia gravis, ocular myasthenia gravis, hypotension, decreased consciousness, circulatory collapse, shock, tachycardia, bradycardia, orthostatic dizziness, orthostatic hypotension, renal impairment, hyperkalemia, angioedema, syncope, vascular edema, erythema, itching, serum sickness, vasculitis, interstitial pneumonia, hypoglycemia, shock, loss of consciousness, agranulocytosis, leukopenia, thrombocytopenia, reduced erythrocyte volume, decreased hemoglobin.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a container that protects it from light. Additionally, it is recommended to store the medication at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness and safety.
Brown oval film-coated tablets
56 tablets (14 tablets/PTP x 4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationValsartan 160mg · Rosuvastatin Calcium Micronized 20.8mg
Tablet · Prescription medication · Combination
LG Chemical Co., Ltd.
CombinationValsartan 80mg · Rosuvastatin Calcium Micronized 20.8mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
CombinationValsartan 160mg · Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
CombinationValsartan 80mg · Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
CombinationValsartan 80mg · Rosuvastatin Calcium Micronized 5.2mg
Tablet · Prescription medication · Combination
LG Chemical Co., Ltd.
CombinationValsartan 160mg · Rosuvastatin Calcium Micronized 5.2mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.